Background/Objectives: Patients on biologic
INTRODUCTION
Psoriasis is one of the most common dermatological conditions, affecting around 2% of the general population in Australia and worldwide. 1 Psoriasis patients have long benefited from ultraviolet light exposure because of its immunosuppressive and subsequent disease modulating effects. 2 Patients with moderate to severe psoriasis are often exposed to systemic immunosuppressive therapies, such as ciclosporin, which increase the risk of solid organ and skin cancers. 3 This may also have an additive mutagenic effect if the patients have had psoralen and ultraviolet-A treatment (PUVA), which independently increases the risk of nonmelanoma skin cancers (NMSCs) 4 and melanomas. 5 The risk of narrowband ultraviolet-B irradiation appears less significant. 6 The risk of development of dysplastic naevi and melanomas in biologic therapy patient cohorts has not yet been determined. Interestingly, psoriasis plaques have been reported to confer a protective mechanism against DNA skin damage from ultraviolet light, and psoriasis itself does not seem to confer an increased risk of skin cancers. 7 In the case of melanoma, the presence of pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6 and tumour necrosis factor-alpha, in psoriatic skin lesions may confer a protective role in melanomagenesis. 8 We aimed to prospectively study a population of psoriasis patients on biologic therapy, which included the three TNF-alpha inhibitors (TNFi), etanercept, infliximab and adalimumab and an IL-12/IL-23 monoclonal antibody, ustekinumab. Follow-up of all pigmented naevi of patients was performed using clinical assessment and sequential digital dermoscopic imaging, as well as total body photography, allowing analysis of the total number of naevi, the proportion of naevi that underwent major or minor dermoscopic changes and the development of dysplastic naevi or melanomas.
METHODS
Consecutive patients, aged at least 18 years, which had been on a biologic agent for a minimum of 6 months were recruited. Patients without a history of psoriasis or conditions that required previous or current immunosuppression, including biologics acted as control. The local Ethics Committee approved the study.
Background history was obtained from all subjects including past and family history of skin cancers, dysplastic naevus syndrome, occupational and recreational sun exposure, history of sunburns and sunbed use and current sun protection practices. A composite score of previous sun exposure and degree of current sun protection was applied as 1 for mild, 2 for moderate and 3 for severe, for an overall impression. A history of repeated childhood sunburns and/or family history of skin cancers, moderate to considerable sun exposure during adolescent and younger adulthood years including sunbed use, and moderate to considerable lack of sun avoidance behaviour in the last 5 years each scored a maximum of 1 mark. Participants were requested to keep a diary to record the number of days of significant sun exposure of over half of the body surface in the full sun greater than 15 min to measure the amount of sun exposure during the study period.
Total body photography of all patients was taken at the baseline visit, as well as photographs of individual pigmented naevi of at least 2 mm in diameter, using a sequential digital dermoscopic imaging device (SolarScan, Polartechnics, Sydney, NSW, Australia). If there were uncertainties about the nature of the pigmented lesion, it was still photographed at baseline. Closer examination with a hand-held dermatoscope determined whether it was a melanocytic naevus or not. If a lesion did not turn out to be a naevus, the baseline photograph was excluded from the count and the lesion was not followed up. The entire integument, with the exception of genitalia, was examined.
If patients had any known naevi or lesions in the genital area, these were also monitored with the patient's permission.
SolarScan captures dermoscopic images of lesions at a magnification of 912.5, and is colour-calibrated for uniformity of illumination at the beginning of each daily session and for each lesion capture. 9 Therefore, variation in the overall colour acquisition at different time points is kept to a minimum. Lesion size was determined using the built-in measurement function of the Solarscan software. Using this function, the investigator defines the lesion edges and diameters and the instrument automatically calculates the measurements. Dermoscopic pictures were usually taken by the same investigator using consistent light pressure so as to not alter the quality of the image. The same orientation of the image capture was ensured at follow-up for ease of comparison with the baseline images. If there were suspicious features at baseline or follow up, the lesion was either excised or underwent 3 months short-term monitoring, depending on the degree of clinical suspicion. 9 A diagnosis of benign or dysplastic naevi was clinically determined and confirmed by histopathological assessment of the excised specimen according to the expert opinion of a histopathologist. 10 Dermoscopic changes were categorised into four major and four minor change types according to Kittler and colleagues. 11 The major changes were: (i) enlargement; (ii) decrease in size (regression); (iii) colour changes (appearance of new colours); and (iv) structural changes (i.e. appearance of melanoma-associated structures, such as changes in pigment network, irregular peripheral dots, radial streaming, blue-white structures and structureless areas). The minor changes included: (i) homogenous lightening of pigment network; (ii) homogenous darkening of pigment network; (iii) increase or decrease of number of brown globules; and (iv) diffuse light brown pigmentation replacing parts of the pigment network. Each naevus was compared side by side for any dermoscopic major or minor changes on digital images. Comparison was performed and recorded by one consistent examiner (dermatology registrar). If there was any ambiguity regarding the type of changes, a senior dermatologist was consulted. Enlargement and regression denoted any perceivable increase or decrease in size of the lesion, and the built-in measurement function of the Solarscan was utilised by appointing two points on the screen to measure the distance.
Any surrounding skin colour change was also noted for all naevi as a measure of degree of recent sun exposure during the study period. This was performed by direct visual comparison, as there were no available tools, such as a spectrometer. A slight variation in hue was allowed to account for variation in lighting; otherwise changes to a lighter or darker colour were recorded.
Analysis of the lesions could not be blinded, as both the total body photography and the dermoscopic images saved in Solarscan required the entry of patients' names, which were displayed on the computer screen during review of the images.
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As the number of patients was low in some of the Fitzpatrick skin types, they were divided into two groups: skin types I-II for the fair-skinned and their burn tendency (fairer), and types III-IV for darker skin types and their tan tendency with sun exposure (darker).
Statistical analysis
Given that 4% of pigmented naevi undergo major dermoscopic changes annually, 11 power was calculated with an assumption that 6% of naevi may undergo major dermoscopic changes in the biologics group. To demonstrate a statistically significant difference at a P value of 0.05%, the sample size required to satisfy 80% power was 1849 naevi examined in each group. With an estimated mole count of up to 50 per person on average, 12 this equated to at least 37 patients for each group. Univariate analysis was conducted using Pearson's chisquare test when comparing categorical variables and independent t-test when comparing numeric variables. To examine the significance of changes in naevi, a negative binomial regression model was used to calculate the rate of changes in naevi between the two groups. The proportion of changes was calculated as the number of naevi with changes against the total number of naevi for each patient. The incidence rate ratio (IRR) was used to quantify the increased risk for those in the psoriasis group versus the control and its 95% confidence interval (CI). Both unadjusted IRR and IRR adjusted for both skin colour types (fairer vs darker) and lengths of follow-ups are presented.
RESULTS

Patient baseline characteristics
Forty eight patients with psoriasis on biologics were recruited, with 45 completing the follow-up visits. They were on etanercept (5 patients), adalimumab (13), infliximab (15) and ustekimumab (12) . Forty seven control patients were recruited, with 43 completing the follow-up visits. There were no significant differences in the baseline characteristics regarding numbers of patients, age, gender, past or family history of NMSCs or melanomas or follow-up period between the study and control groups (Table 1) . There were more fair-skinned individuals in the control than the study group (74% vs 44%; P = 0.004). Although the patients were randomly recruited, a possible consideration for this difference is that more fair-skinned individuals may have volunteered to be a part of the study because of their vested interest in being aware of their risk of changes in naevi compared with individuals with darker skin types. This difference in skin types was adjusted for in the subsequent analysis.
Sun exposure
Recent sun exposure is known to cause dermoscopic change in naevi. 13 The baseline mean previous sun exposure score was comparable between the two groups (1.9 vs 2.1; P = 0.20). During the study period, 16% and 14% of patients in the study and control groups completed the sun exposure diary (P = 0.83). However, because of the low response rate, this was not considered further in the analysis. The background skin colour change surrounding each naevus was assessed as a measure of recent sun exposure. No recent background skin colour change had occurred in 95% of naevi in the study and 96% of naevi in the control group; however there was a statistically significant difference in the naevi that had become lighter, reflecting 3% of the total naevi in study and 1.8% in control patients (P = 0.016). Although statistically significant, this small difference is not clinically relevant. Furthermore, there was no statistically significant difference between the two groups in the background skin colour of patients with naevi that underwent major dermoscopic changes (P = 0.86; Table 2 ).
Observation of changes in naevi over the monitored period
There was no significant difference in the mean followup period between the groups (1.4 years in the study group, 1.6 years in the control, 95% CI À0.96 to 0.40; P = 0.23).
A total of 2708 and 3017 naevi were followed in 45 study and 43 control patients, respectively. Although there were 11 patients (23%) in the control group who had over 100 naevi compared to five study patients (11%), there was no significant difference in the overall number of naevi per person between the groups (60.2 naevi per person in the study group and 70.2 naevi in the control, 95% CI À26.24 to 6.24; P = 0.23).
A total of 88 major changes (54 enlargements, 24 regressions, four colour changes and six structural changes) were noted in 80 naevi in 33 patients (73.3%) in the study group. Sixty-two major changes (40 enlargements, 11 regressions, eight colour changes and three structural changes) were found in 57 naevi in 27 patients (62.8%) in the control group. This difference was not significant in terms of the number of patients affected (P = 0.29; Supplementary Table 1 ). The rate of naevi with major changes per patient's total number of naevi was higher in the study group (80 vs 57 naevi in the control) but failed to reach significance (IRR = 1.51, 95% CI 0.96 to 2.36; P = 0.075). This was also non-significant when fairer (Fitzpatrick skin types I and II) or darker (Fitzpatrick skin types III-VI) skin types were adjusted for (IRR = 1.44, 95% CI 0.89 to 2.34; P = 0.14). The rate of naevi with major changes was also higher in the study group by 45% after adjusting for both patient skin types and the follow-up period per individual patient; however this was not statistically significant (IRR = 1.45, 95% CI 0.90 to 2.33; P = 0.125).
There were 430 minor changes (417 lighter pigment network, eight darker pigment network, two brown globules and three diffuse light brown pigmentation) observed in 430 naevi in 42 (93.3%) biologic patients, and 585 minor changes (555 lighter pigment network, 22 darker pigment e16 SD Choi et al.
network, eight brown globules) observed in 585 naevi in 41 (95.3%) control patients, which was comparable in terms of number of subjects affected in each group (P = 0.69; Supplementary Table 2 ). The proportion of naevi with minor changes in the study group was lower but the result was not significant (IRR = 0.76, 95% CI 0.56 to 1.03; P = 0.08). After adjusting for fairer and darker skin types, the difference was still not significant (IRR = 0.77, 95% CI 0.55 to 1.06; P = 0.11). Furthermore, after adjusting for both skin types and the follow-up period, the difference was not statistically significantly lower in the study group (IRR = 0.77, 95% CI 0.57 to 1.08; P = 0.14).
No melanomas were identified in either group during the study period. Four (8.9%) biologic patients developed a total of six new dysplastic naevi compared with four (9.3%) control patients who developed four new dysplastic naevi collectively, as confirmed by histopathology. The relative risk (RR) of a biologic patient developing a dysplastic naevus compared to the control group was not significant (RR = 0.96, 95% CI À0.12 to 0.12), and the proportion of patients who developed dysplastic naevi was not significantly different between the two groups (P = 0.95).
The duration of biologic treatment in the four patients who developed dysplastic naevi was shorter (mean 3.5 years, standard deviation [SD] 0.55) compared with the remainder of the biologic treatment group (mean 4.6 years, SD 2.5), but this outcome was not statistically significant (P = 0.39). 18 (40) 10 ( Because of the small number of participants with skin types I, IV, V and VI, they were grouped into fairer and darker skin types. SD, standard deviation. Number of naevi with a major change with no surrounding skin colour change, n/n naevi with major changes (%) 15 However, comparison skin cancer prevalence data for the general population was derived from the National Cancer Institute from a survey of eight locations in the United States from 1977 to 1978, which was almost 30 years prior to adalimumab being available on the market; as skin cancer rates have increased over the years, this may have contributed to an overestimation of the incidence rates. Previous studies and case reports of biologics, including TNFi increasing the rate of NMSCs does not justify a cause-effect hypothesis, because previous immunosuppressive therapies are known to increase the risk of skin cancers, such as cyclosporine and PUVA. 16 The risk of skin cancers in severe psoriasis patients needs to be studied separately as their position is unique as a separate disease entity, as a result of phototherapy exposure (in particular PUVA), and because of their tendency to have spent more time outdoors. In 2017, the only prospective study conducted to date for this purpose was published by an Italian group and found no significant changes in the naevi count or dermoscopic features of naevi between biological and conventional treatment with methotrexate or ciclosporin; however, only one out of 67 patients administered biologic therapy showed a dermoscopically changed naevus. 17 A 2015 Australian study found that naevi continue to change in size throughout adulthood, independent of immunosuppression. Nevertheless, this study was performed with a study population of 29 individuals at high risk of melanoma. 18 There is no firm evidence that the use of biologics in the psoriasis population confers an independent increased risk of melanomas. The risk of melanoma is reported to significantly increase 1.5 fold (95% CI 1.0 to 2.2) in patients with rheumatoid arthritis on a TNFi compared to those on nonbiological treatment. 19 However, a recent collaborative analysis of nine European registries showed no significant difference in melanoma incidence between biologic-na€ ıve patients and those exposed to TNFi or other biologics, with pooled standard IRRs of 1.1 (95% CI 0.9 to 1.4) and 1.2 (95% CI 0.99 to 1.6), respectively. 20 Importantly, we do not know the rates of changes in naevi in the psoriasis population, and whether biologic therapy impacts the biology of melanocytic lesions over time. While dysplastic naevi are associated with a higher risk of developing melanomas, [21] [22] [23] they are a low-risk melanoma precursor, with only 1 in 11 000-77 000 dysplastic naevi estimated to transform into a melanoma per year. 24 
CONCLUSION
This study concludes that psoriasis patients on biologic treatment do not have an increased risk of developing major dermoscopic changes in naevi or dysplastic naevi over a 1.5 year duration. This study has shown that at least clinically, there appears to be no increased risk of changes in melanocytic lesions in patients on biologic therapy. A limitation, however, is that the study period of 1.5 years may not be sufficient to detect all changes in naevi and is not powered to detect changes in melanoma incidence. A large-scale prospective observational study with a longerterm follow-up period would add much value to the literature. Further added limitations of this study include the subjective nature of assessment of previous sun exposure history prior to the study entry, the lack of objective assessment of colour changes (e.g., with the use of spectrometry) and potential minor alternations in the appearance of the colour and size of the lesion depending on how much pressure was applied to the skin when capturing the image.
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